Literature DB >> 19782880

Pluripotent stem cells as new drugs? The example of Parkinson's disease.

Olivier Preynat-Seauve1, Pierre R Burkhard, Jean Villard, Walter Zingg, Nathalie Ginovart, Anis Feki, Michel Dubois-Dauphin, Samia A Hurst, Alex Mauron, Marisa Jaconi, Karl-Heinz Krause.   

Abstract

Cell replacement therapy is a widely discussed novel concept of medical treatment. The increased knowledge in the stem cell field, particularly pluripotent stem cells, potentially provides powerful tools for this therapeutic concept. A large number of disease characterized by the loss of functional cells are potential candidates for cell replacement therapy and, in this regards, Parkinson's disease is of particular interest. It is one of the most prevalent neurodegenerative diseases caused by the loss of dopaminergic neurons in the Substantia nigra pars compacta. Pharmacological therapies are valuable but suffer from the progressive decline of efficacy as the disease progresses. Cell therapy application has emerged about two decades ago as a valid therapeutic alternative and recent advances in stem cell research suggest that pluripotent stem cell transplantation may be a promising approach to replace degenerated neurons in Parkinson's disease. Various sources of pluripotent stem cells (PSC) currently tested in animal models of Parkinson's disease have proven their efficacy in relieving symptoms and restoring damaged brain function. This review summarizes and discusses the important challenges that actually must be solved before the first studies of PSC transplantation can be undertaken into humans.

Entities:  

Mesh:

Year:  2009        PMID: 19782880     DOI: 10.1016/j.ijpharm.2009.03.003

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  5 in total

1.  Neurogenic potential of progenitor cells isolated from postmortem human Parkinsonian brains.

Authors:  Shanshan Wang; Michael S Okun; Oleg Suslov; Tong Zheng; Nikolaus R McFarland; Vinata Vedam-Mai; Kelly D Foote; Steven N Roper; Anthony T Yachnis; Florian A Siebzehnrubl; Dennis A Steindler
Journal:  Brain Res       Date:  2012-04-27       Impact factor: 3.252

Review 2.  Stem cell sources for regenerative medicine: the immunological point of view.

Authors:  Olivier Preynat-Seauve; Karl-Heinz Krause
Journal:  Semin Immunopathol       Date:  2011-05-21       Impact factor: 9.623

3.  Considerations regarding the etiology and future treatment of autosomal recessive versus idiopathic Parkinson disease.

Authors:  Tohru Kitada; Julianna J Tomlinson; Hei Sio Ao; David A Grimes; Michael G Schlossmacher
Journal:  Curr Treat Options Neurol       Date:  2012-06       Impact factor: 3.598

Review 4.  Adapting Preclinical Benchmarks for First-in-Human Trials of Human Embryonic Stem Cell-Based Therapies.

Authors:  Gaia Barazzetti; Samia A Hurst; Alexandre Mauron
Journal:  Stem Cells Transl Med       Date:  2016-06-22       Impact factor: 6.940

Review 5.  Stem cells in clinical practice: applications and warnings.

Authors:  Daniele Lodi; Tommaso Iannitti; Beniamino Palmieri
Journal:  J Exp Clin Cancer Res       Date:  2011-01-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.